Study Using CABENUVA™ for the Treatment of Human Immunodeficiency Virus (HIV)-1, Administered in Infusion Centers (IC) or Alternate Sites of Administration (ASA) in the United States (U.S.)

Inclusion criteria

• Adults (greater than or equal to [>=]18 years old) at the time of signing the informed consent.

• HIV-1 infected and have been prescribed CABNEUVA per the United States Prescribing information (USPI).

• Participants can be enrolled

• If they have been taking oral VOCABRIA + EDURANT or other ART for approximately 1 month (at least 28 days) prior to Baseline/Month 1, or

• Already taking CABENUVA prior to Baseline/Month 1 and the last injections were within a 1 month +/- 7-day window or for every 2-month injections, the timing will vary if they are receiving the initiation injections (1 month +/- 7-day) or the continuation injections (2 months +/- 7 days) per the USPI, or

• Prescribed direct to inject and receive their 1st injection without an oral lead in at the Infusion Center/ASA on the last day of any other antiretroviral therapy

• Agreement to receive CABENUVA IM injections at participating infusion center/ASA.

Exclusion criteria

• Participants are excluded from the study as dictated in the Prescribing Information (CABENUVA [USPI]) in consultation with the HIV care provider.

• Contraindications, as per the current Prescribing Information [CABENUVA USPI]

• New health condition / prohibited medication reported - Other Reason at the discretion of the HIV care provider or IC/ ASA staff